GLP1-T-30 Reference-Code Fill

The 30 mg fill sits at the cost-equilibrium point of the T-series: smaller than the 60 mg vial enough to suit dispensing fractionation into more common compounding-pharmacy sizes (5 mg, 10 mg, 15 mg), larger than the 10 mg vial enough to amortize the per-vial overhead cost (lyophilization, packaging, QC release). For distributor partners building inventory across multiple dispensing-fill sizes downstream, the 30 mg is the most operationally efficient bulk unit. Buyers should still confirm the API identity (Tirzepatide-class material per the 'T' designation) against the batch-specific COA at receipt regardless of fill size choice.

At 30 mg total mass and assuming standard Tirzepatide-class dispensing doses (5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg per dose for common protocols), a single GLP1-T-30 vial supports: 6 doses at 5 mg, 4 doses at 7.5 mg, 3 doses at 10 mg, or 2 doses at 15 mg. Pharmacies running mixed-protocol dispensing typically extract multiple smaller doses per vial through sterile preparation under ISO 7/8 conditions; the limiting factor is contamination risk and shelf life of the reconstituted material rather than the total available mass. For larger dispensing throughput, the GLP1-T-60 fill at 60 mg total mass doubles the per-vial yield with similar per-mg cost economics.

Lead times for the reference-code SKU family follow the standard PeptideXpo schedule: 14-21 days for first-time orders from confirmed PO, dropping to 10-14 days for repeat orders against an established synthesis route. The first-time order timeline includes (1) the NDA + spec-sheet confirmation step, (2) batch release-testing scope agreement, and (3) the actual synthesis and QC release. Repeat orders skip the first two steps because the documentation is already in place. For distributor partners with recurring procurement schedules, PeptideXpo can hold released-batch inventory against quarterly forecast orders to compress effective lead time further, discuss the procurement schedule at quote stage.